BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 20367108)

  • 21. Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites.
    Dalvie D; Obach RS; Kang P; Prakash C; Loi CM; Hurst S; Nedderman A; Goulet L; Smith E; Bu HZ; Smith DA
    Chem Res Toxicol; 2009 Feb; 22(2):357-68. PubMed ID: 19146377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimating drug solubility in the gastrointestinal tract.
    Dressman JB; Vertzoni M; Goumas K; Reppas C
    Adv Drug Deliv Rev; 2007 Jul; 59(7):591-602. PubMed ID: 17599644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An update on computational oral absorption simulation.
    Dressman JB; Thelen K; Willmann S
    Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1345-64. PubMed ID: 21939427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cunninghamella--a microbial model for drug metabolism studies--a review.
    Asha S; Vidyavathi M
    Biotechnol Adv; 2009; 27(1):16-29. PubMed ID: 18775773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predicting human pharmacokinetics from preclinical data.
    Poggesi I
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):100-11. PubMed ID: 14982153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Computational science in drug metabolism and toxicology.
    Valerio LG
    Expert Opin Drug Metab Toxicol; 2010 Jul; 6(7):781-4. PubMed ID: 20465524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A structural feature-based computational approach for toxicology predictions.
    Valerio LG; Yang C; Arvidson KB; Kruhlak NL
    Expert Opin Drug Metab Toxicol; 2010 Apr; 6(4):505-18. PubMed ID: 20074001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
    Lüpfert C; Reichel A
    Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates.
    Kortejärvi H; Urtti A; Yliperttula M
    Eur J Pharm Sci; 2007 Feb; 30(2):155-66. PubMed ID: 17187967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism.
    Baillie TA
    Chem Res Toxicol; 2008 Jan; 21(1):129-37. PubMed ID: 18052111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Computational methods to predict the reactivity of nanoparticles through structure-property relationships.
    Poater A; Gallegos Saliner A; Solà M; Cavallo L; Worth AP
    Expert Opin Drug Deliv; 2010 Mar; 7(3):295-305. PubMed ID: 20201736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decontamination and detoxification strategies for the Fusarium mycotoxin deoxynivalenol in animal feed and the effectiveness of microbial biodegradation.
    Awad WA; Ghareeb K; Bohm J; Zentek J
    Food Addit Contam Part A Chem Anal Control Expo Risk Assess; 2010 Apr; 27(4):510-20. PubMed ID: 20234966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Probiotics, prebiotics, and synbiotics.
    de Vrese M; Schrezenmeir J
    Adv Biochem Eng Biotechnol; 2008; 111():1-66. PubMed ID: 18461293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early prediction of drug metabolism and toxicity: systems biology approach and modeling.
    Bugrim A; Nikolskaya T; Nikolsky Y
    Drug Discov Today; 2004 Feb; 9(3):127-35. PubMed ID: 14960390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human CYPs involved in drug metabolism: structures, substrates and binding affinities.
    Lewis DF; Ito Y
    Expert Opin Drug Metab Toxicol; 2010 Jun; 6(6):661-74. PubMed ID: 20402561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Altered nonrenal drug clearance in ESRD.
    Nolin TD
    Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):555-9. PubMed ID: 18941346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting ADME properties and side effects: the BioPrint approach.
    Krejsa CM; Horvath D; Rogalski SL; Penzotti JE; Mao B; Barbosa F; Migeon JC
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):470-80. PubMed ID: 12951810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I).
    Fernández-Teruel C; Nalda Molina R; González-Alvarez I; Navarro-Fontestad C; García-Arieta A; Casabó VG; Bermejo M
    Eur J Pharm Sci; 2009 Jan; 36(1):137-46. PubMed ID: 19028574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and validation of in silico models for estimating drug preformulation risk in PEG400/water and Tween80/water systems.
    Crivori P; Morelli A; Pezzetta D; Rocchetti M; Poggesi I
    Eur J Pharm Sci; 2007 Nov; 32(3):169-81. PubMed ID: 17714921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.